2023 Idaho Pharmacy Technician Criticality Survey (42 Responses)	42
CONTENT STANDARD 1.0: PROFESSIONAL ORGANIZATIONS AND LEADERSHIP	
Performance Standard 1.1: Effective Leadership and Participation in Career Technical Student Organizations (CTSO) and	
Professional Associations	
1.1.1 Explore the role of professional organizations and/or associations in the pharmacy services industry.	1.18
1.1.2 Participate in content aligned CTSO.	1.36
1.1.3 Participate in a CTSO event at the local level or above.	1.18
1.1.4 Engage in career exploration and development through CTSO participation.	1.50
CONTENT STANDARD 2.0: PHARMACY TECHNICIAN	
Performance Standard 2.1: Roles and Services	
2.1.1 Describe the role of the pharmacist.	2.55
2.1.2 Describe the traditional and the advanced role of the pharmacy technician.	2.36
2.1.3 Identify the role of the prescriber.	2.43
2.1.4 Describe the prescription cycle.	2.64
2.1.5 Compare types of pharmacies and other pharmacy services.	1.84
2.1.6 Describe wellness programs offered through pharmacies.	1.52
CONTENT STANDARD 3.0: LEGAL AND ETHICAL RESPONSIBILITIES	
Performance Standard 3.1: Duties According to Regulations, Policies, and Laws	
3.1.1 Describe Idaho State Board of Pharmacy Code and Administrative Rules and its function as it pertains to pharmacy technicians.	2.60
3.1.2 Describe the requirements for pharmacy record keeping.	2.45
3.1.3 Summarize timelines regarding federal laws.	1.93
3.1.4 Compare licensure, certification, registration, and legislated scope of practice of pharmacy professionals.	1.95
3.1.6 Describe the Health Information Portability Accountability Act (HIPAA) and its function.	2.86
3.1.7 Describe the Health Information Technology for Economic and Clinical Health Act (HITECH) and its function.	1.88
2.4.0.1.1	2.48
<ul><li>3.1.8 Identify the Drug Enforcement Administration (DEA) Code of Federal Regulations (number validation) and its function.</li><li>3.1.9 Describe the role of the Food and Drug Administration (FDA).</li></ul>	2.14
3.1.9 Describe the role of the Food and Drug Administration (FDA). 3.1.10 Describe the related guidelines of the Occupational Safety and Health Administration (OSHA) and safety data sheets	2.14
(SDS) and their functions.	2.21
3.1.11 Distinguish between PTCB and NHA certifying bodies in the pharmacy industry.	1.69
3.1.12 Describe continuing education and training requirements for certification and renewal.	2.40
3.1.13 Describe the process of identifying and reporting theft within the pharmacy (DEA Form 106).	2.19
Performance Standard 3.2: Professional Standards and Interpersonal Skills	
3.2.1 Identify personal traits and attitudes of effective pharmacy team members.	1.71
3.2.2 Describe chain of command in a pharmacy setting.	2.36
3.2.3 Demonstrate professional standards of pharmacy workers as they apply to hygiene, dress, language, confidentiality,	2.74
ethical and respectful behavior, and substance and alcohol use and abuse.	2.17
3.2.4 Describe drug diversion.	2.57
3.2.5 Describe the implications of personal and professional social media use as it relates to employment.	2.02
CONTENT STANDARD 4.0: PROCESSING AND HANDLING OF MEDICATION AND MEDICATION	
ORDERS/PRESCRIPTIONS	
Performance Standard 4.1: Prescription Analysis	
4.1.1 Describe the differences between a prescription and a medication order.	2.21
4.1.2 Interpret a prescription.	2.67
4.1.3 Interpret a medication order.	2.50
Performance Standard 4.2: Assisting the Pharmacist	
4.2.1 Input pharmacy data (e.g., patient and insurance profile, prescriptions), using technology.	2.46
4.2.2 Demonstrate knowledge of the prescription refill process.	2.63
	2.46
4.2.3 Identify the patient's need for pharmacy counseling.	2.40

Performance Standard 4.3: Special Pharmacy Operations   1     4.3.1 Describe the phases of investigational drugs in clinical trials.   1     4.3.2 Identify drugs categorized under Risk Evaluation Mitigation Strategies (REMS) and the reasons for that categorization.   1     4.3.2 Identify drugs categorized under Risk Evaluation Mitigation Strategies (REMS) and the reasons for that categorization.   2     4.3.3 Describe afe handling of all pharmaceutical hazardous materials and waste.   2     CONTENT STANDARD 5.0: STERILE AND NON-STERILE COMPOUNDING   1     Performance Standard 5.1: Sterile Compounding.   1     5.1.1 Describe Universal precatutions for sterile compounding.   1     5.1.2 Identify the required ingredients for a compounded sterile product.   1     5.1.3 Identify the equipment and technology used in sterile compounding.   1     5.2.1 Describe universal precatutions for non-sterile compounding.   1     5.2.2 Describe universal precatutions for non-sterile compounding.   1     5.2.3 Identify the required ingredients for a compounded non-sterile product.   1     5.2.4 Identify the equipment and technology used in non-sterile compounding.   1     5.2.3 Identify the required ingredients for a compounded non-sterile compounding.   1     5.2.4 Identify the equipment and technology used in non-sterile compounding.   1		
4.3.1 Describe the phases of investigational drugs in clinical trials.   1.     4.3.2 Identify drugs categorized under Risk Evaluation Mitigation Strategies (REMS) and the reasons for that categorization.   1.     4.3.3 Describe safe handling of all pharmaceutical hazardous materials and waste.   2.     CONTENT STANDARD 5.0: STERILE AND NON-STERILE COMPOUNDING   2.     Performance Standard 5.1: Sterile Compounding.   1.     5.1.1 Describe Universal precautions for sterile compounding.   1.     5.1.2 Describe Universal precautions for sterile compounding.   1.     5.1.3 Identify the required ingredients for a compounded sterile product.   1.     5.1.4 Identify the equired ingredients for a compounding.   1.     5.2.1 Describe Universal precautions for non-sterile compounding.   1.     5.2.2 Describe Universal precautions for non-sterile compounding.   1.     5.2.3 Identify the required ingredients for a compounded non-sterile product.   1.     5.2.4 Identify the required ingredients for a compounding.   1.     5.2.5 Demonstrate the processe and procedures of non-sterile compounding.   1.     6.1.2 Define the term third party.   2.     6.1.2 Define the term third party.   2.     6.1.3 Describe the fields on an insurance card.   2.     6.1.4 Describe phareacy reliabu	4.2.5 Describe a pharmacy technician's role in an audit.	1.98
4.3.2 Identify drugs categorized under Risk Evaluation Mitigation Strategies (REMS) and the reasons for that categorization.   1.     4.3.3 Describe safe handling of all pharmaceutical hazardous materials and waste.   2.     CONTENT STANDARD 5.0: STERILE AND NON-STERILE COMPOUNDING   2.     Performance Standard 5.1: Sterile Compounding.   1.     5.1.1 Describe Universal precautions for sterile compounding.   1.     5.1.2 Describe Universal precautions for sterile compounding.   1.     5.1.3 Identify the required ingredients for a compounded sterile product.   1.     5.1.4 Identify the equipment and technology used in sterile compounding.   1.     5.2.1 Describe UNIVERSI proceedimes of sterile compounding.   1.     5.2.2 Describe USP Guideline 795 and its function.   1.     5.2.3 Identify the equired ingredients for a compounded non-sterile compounding.   1.     5.2.4 Identify the equired ingredients for a compounded non-sterile compounding.   1.     5.2.5 Demonstrate the processes and procedures of non-sterile compounding.   1.     6.1.1 Define the term third patry.   2.     6.1.2 Describe USP Guideline 708   2.     6.1.1 Define the term third patry.   2.     6.1.2 Describe the fields on an insurance billing (e.g., prior authorizations, deductible, double billing) when supplies are billed as durable as una	Performance Standard 4.3: Special Pharmacy Operations	
4.3.2 learning   2     CONTENT STANDARD 5.0: STERILE AND NON-STERILE COMPOUNDING   2     Performance Standard 5.1: Sterile Compounding   1     5.1.1 Describe universal precautions for sterile compounding.   1     5.1.2 Describe universal precautions for sterile compounding.   1     5.1.3 Learning universal precautions for sterile compounding.   1     5.1.3 learning universal precautions for sterile compounding.   1     5.1.3 learning the equipment and technology used in sterile compounding.   1     5.1.3 learning the equipment and technology used in sterile compounding.   1     5.2.1 Describe universal precautions for sterile compounding.   1     5.2.2 Describe USP Guideline 795 and its function.   1     5.2.3 learning the required ingredients for a compounded non-sterile product.   1     5.2.4 identify the equipment and technology used in non-sterile compounding.   1     6.1.2 Define the term third party.   2     6.1.2 Define the term third party.   2     6.1.3 Describe thirds party rejections and the reasons they occur.   2     6.1.4 Describe pharmacy reimbursement plans.   1     6.1.2 Define the term third party.   2     6.1.3 Describe the fields on an insurance card.   2	4.3.1 Describe the phases of investigational drugs in clinical trials.	1.12
4.3.3 Describe safe handling of all pharmaceutical hazardous materials and waste.   2.     CONTENT STANDARD 5.0: STERILE AND NON-STERILE COMPOUNDING      Performance Standard 5.1: Sterile Compounding   1.     5.1.1 Describe universal precautions for sterile compounding.   1.     5.1.2 Describe United States Pharmacopeia (USP) Guidelines 797 and 800 and their functions.   1.     5.1.3 Identify the required ingredients for a compounded sterile product.   1.     5.1.4 Identify the equipement and technology used in sterile compounding.   1.     5.2.1 Describe universal precautions for non-sterile compounding.   1.     5.2.2 Describe USP Guideline 795 and its function.   1.     5.2.3 Identify the required ingredients for a compounded non-sterile product.   1.     5.2.4 Identify the equipement and technology used in non-sterile compounding.   1.     5.2.5 Demonstrate the processes and procedures of non-sterile compounding.   1.     5.2.5 Demonstrate the processes and procedures of non-sterile compounding.   1.     6.1.2 Define the term third party.   2.     6.1.2 Define the term third party.   2.     6.1.2 Define the term third party.   2.     6.1.3 Describe the fields on an insurance billing (e.g., prior authorizations, deductible, double billing) when suppiles are billed as durable medical equipment.	1.3.2 Identify drugs categorized under Risk Evaluation Mitigation Strategies (REMS) and the reasons for that categorization	1.90
CONTENT STANDARD 5.0: STERILE AND NON-STERILE COMPOUNDING     Performance Standard 5.1: Sterile Compounding     S.1.1 Describe universal precatitions for sterile compounding.     S.1.2 Describe United States Pharmacopeia (USP) Guidelines 797 and 800 and their functions.     S.1.3 dentify the required ingredients for a compounded sterile product.     S.1.4 Identify the equipment and technology used in sterile compounding.     S.1.5 Describe universal precautions for sterile compounding.     Performance Standard 5.2: Non-Sterile Compounding.     S.2.1 Describe universal precautions for non-sterile compounding.     S.2.1 Describe USP Guideline 795 and its function.     S.2.2 Obscribe USP Guideline 795 and its function.     S.2.4 Identify the requirement and technology used in non-sterile compounding.     S.2.4 Identify the equipment and technology used in non-sterile compounding.     CONTENT STANDARD 6.0: PROCUREMENT, BILLING, REIMBURSEMENT, AND INVENTORY MANAGEMENT     Performance Standard 6.1: Adjudication of Billing     6.1.2 Define the term third party.     6.1.3 Describe the fields on an insurance card.     6.1.4 Describe pharmacy reimbursement plans.     6.1.5 Describe the fields on an insurance card.     6.1.2 Define the term third party.     6.1.3 Describe the fields on an insurance card.     6.1.4 Describe third-party rejections and the reasons thy occur. </td <td></td> <td>2.29</td>		2.29
Performance Standard 5.1: Sterile Compounding     1.       5.1.1 Describe United States Pharmacopied (USP) Guidelines 797 and 800 and their functions.     1.       5.1.2 Describe United States Pharmacopied (USP) Guidelines 797 and 800 and their functions.     1.       5.1.3 Identify the required ingredients for a compounded sterile product.     1.       5.1.4 Identify the equipment and technology used in sterile compounding.     1.       5.1.5 Demonstrate the processes and procedures of sterile compounding.     1.       5.2.1 Describe universal precautions for non-sterile compounding.     1.       5.2.2 Describe USP Guideline 795 and its frunction.     1.       5.2.3 Identify the equipment and technology used in non-sterile compounding.     1.       5.2.5 Demonstrate the processes and procedures of non-sterile compounding.     1.       5.2.5 Demonstrate the processes and procedures of non-sterile compounding.     1.       6.1.1 Define the term third party.     2.       6.1.2 Define the term third party.     2.       6.1.3 Describe the fields on an insurance card.     2.       6.1.4 Describe pharmacy reimbursement plans.     1.       6.1.5 Describe theride party rejections and the reasons they occur.     2.       6.2.1 Describe various procedures of nuprchasing pharmaceuticals.     2.		2.29
5.1.1 Describe universal precautions for sterile compounding.   1.     5.1.2 Describe United States Pharmacopeia (USP) Guidelines 797 and 800 and their functions.   1.     5.1.3 Identify the required ingredients for a compounded sterile product.   1.     5.1.4 Identify the equired ingredients for a compounded sterile product.   1.     5.1.5 Demonstrate the processes and procedures of sterile compounding.   1.     5.2.1 Describe universal precautions for non-sterile compounding.   1.     5.2.2 Describe USP Guideline 795 and its function.   1.     5.2.3 Identify the required ingredients for a compounded non-sterile product.   1.     5.2.4 Identify the equipment and technology used in non-sterile compounding.   1.     5.2.5 Demonstrate the processes and procedures of non-sterile compounding.   1.     CONTENT STANDARD 6.0: PROCUREMENT, BILLING, REIMBURSEMENT, AND INVENTORY MANAGEMENT   2.     Performance Standard 6.1: Adjudication of Billing   2.     6.1.2 Define the term third party.   2.     6.1.2 Define the term bindry rejections and the reasons they occur.   2.     6.1.3 Describe the fields on an insurance card.   2.     6.1.4 Describe the fields on an insurance ard.   2.     6.1.5 Describe the term bindry rejections and the reasons they occur.   2.     7.1 Descri		<u> </u>
5.1.2 Describe United States Pharmacopeia (USP) Guidelines 797 and 800 and their functions.   1.     5.1.3 Identify the required ingredients for a compounded sterile product.   1.     5.1.4 Identify the equipment and technology used in sterile compounding.   1.     5.1.5 Demonstrate the processes and procedures of sterile compounding.   1.     Performance Standard 5.2: Non-Sterile Compounding.   1.     5.2.1 Describe universal precaturos for non-sterile compounding.   1.     5.2.2 Describe USP Guideline 795 and its function.   1.     5.2.3 Lenscribe universal precaturos for non-sterile compounding.   1.     5.2.4 Identify the required ingredients for a compounded non-sterile product.   1.     5.2.5 Demonstrate the processes and procedures of non-sterile compounding.   1.     CONTENT STANDARD 6.0: PROCUREMENT, BILLING, REIMBURSEMENT, AND INVENTORY MANAGEMENT   2.     Performance Standard 6.1: Adjudication of Billing   2.     6.1.2 Define the term third party.   2.     6.3.2 Describe the fields on an insurance card.   2.     6.3.4 Describe pharmacy reimbursement plans.   1.     6.3.5 Describe bird-party rejections and the reasons they occur.   2.     Performance Standard 6.2: Purchasing Pharmaceuticals.   1.     6.2.1 Describe various procedures in purchasing pharma		1.02
5.1.3 Identify the required ingredients for a compounded sterile product.   1.     5.1.4 Identify the equipment and technology used in sterile compounding.   1.     Performance Standard 5.2: Non-Sterile Compounding.   1.     Second Standard 5.1: Adjudication on-sterile compounding.   1.     Second Standard 6.1: Adjudication of Billing   1.     CONTENT STANDARD 6.0: PROCUREMENT, BILLING, REIMBURSEMENT, AND INVENTORY MANAGEMENT   2.     Performance Standard 6.1: Adjudication of Billing   2.     6.1.2 Define the term third party.   2.     6.1.3 Describe the fields on an insurance card.   1.     6.1.4 Describe pharmacy relimbursement plans.   1.     6.1.5 Describe third-party rejections and the reasons they occur.   2.     Performance Standard 6.3: Inventory Control systems (DEA Form 222).   1.     6.3.1 Describe the fields on an insurance card.   1.     6.3.2 Describe the procedures in purchasing pharmaceuticals.   1.		1.93
5.1.4 Identify the equipment and technology used in sterile compounding.   1.     5.1.5 Demonstrate the processes and procedures of sterile compounding.   1.     S.1.0 Describe universal precautions for non-sterile compounding.   1.     5.2.1 Describe USP Guideline 795 and its function.   1.     5.2.3 Identify the required ingredients for a compounded non-sterile product.   1.     5.2.4 Identify the equipment and technology used in non-sterile compounding.   1.     5.2.5 Demonstrate the processes and procedures of non-sterile compounding.   1.     CONTENT STANDARD 6.0: PROCUREMENT, BILLING, REIMBURSEMENT, AND INVENTORY MANAGEMENT   Performance Standard 6.1: Adjudication of Billing     6.1.1 Define the term third party.   2.   2.     6.1.2 Define the term third party.   2.     6.1.3 Describe the fields on an insurance billing (e.g., prior authorizations, deductible, double billing) when supplies are billed as durable medical equipment.   2.     6.1.4 Describe pharmacy reimbursement plans.   1.     6.1.5 Describe third-party rejections and the reasons they occur.   2.     9.2 Describe controlled substance ordering systems (DEA Form 222).   1.     6.2.1 Describe third-party rejections and the technology applied.   2.     9.2 Describe the process of return to stock.   2.     6.3.2 Describe the pro		1.83
5.1.5 Demonstrate the processes and procedures of sterile compounding.   1.     Performance Standard 5.2: Non-Sterile Compounding   1.     5.2.1 Describe universal precautions for non-sterile compounding.   1.     5.2.2 describe USP Guideline 795 and its function.   1.     5.2.3 Identify the required ingredients for a compounded non-sterile product.   1.     5.2.4 Identify the equipment and technology used in non-sterile compounding.   1.     5.2.5 Demonstrate the processes and procedures of non-sterile compounding.   1.     CONTENT STANDARD 6.0: PROCUREMENT, BILLING, REIMBURSEMENT, AND INVENTORY MANAGEMENT   Performance Standard 6.1: Adjudication of Billing     6.1.1 Define the term hird party.   2.   2.     6.1.2 Define the term hird party.   2.     6.1.3 Describe the fields on an insurance card.   2.     6.1.4 Describe the fields on an insurance card.   2.     6.1.5 Describe the fields on an insurance card.   2.     6.2.1 Describe various procedures in purchasing pharmaceuticals.   1.     6.2.1 Describe the fields on an insurance card.   2.     6.2.1 Describe the ordering systems (DEA Form 222).   1.     6.3.1 Describe the fields on an user servicus of user servicus and the technology applied.   2.     9erformance Standard 6.3: Inventory Control <td></td> <td>1.85</td>		1.85
Performance Standard 5.2: Non-Sterile Compounding.   1.     5.2.1 Describe universal precautions for non-sterile compounding.   1.     5.2.2 Describe USP Guideline 795 and its function.   1.     5.2.3 Identify the required ingredients for a compounded non-sterile product.   1.     5.2.4 Identify the equipment and technology used in non-sterile compounding.   1.     5.2.5 Demonstrate the processes and procedures of non-sterile compounding.   1.     CONTENT STANDARD 6.0: PROCUREMENT, BILLING, REIMBURSEMENT, AND INVENTORY MANAGEMENT   2.     Performance Standard 6.1: Adjudication of Billing   2.     6.1.1 Define the term third party.   2.     6.1.2 Define the terminology used in insurance billing (e.g., prior authorizations, deductible, double billing) when supplies are billed as durable medical equipment.   2.     6.1.3 Describe third-party rejections and the reasons they occur.   2.     Performance Standard 6.2: Purchasing Pharmaceuticals.   1.     6.1.4 Describe various procedures in purchasing pharmaceuticals.   1.     6.2.1 Describe tworp existems and the reasons they occur.   2.     Performance Standard 6.2: Purchasing Pharmaceuticals.   1.     6.3.1 Describe various procedures in purchasing pharmaceuticals.   1.     6.2.2 Describe various procedures for reviewoug anglied.   1. <td></td> <td>1.90</td>		1.90
5.2.1 Describe universal precautions for non-sterile compounding.   1.     5.2.2 Describe USP Guideline 795 and its function.   1.     5.2.3 Identify the required ingredients for a compounded non-sterile product.   1.     5.2.4 Identify the equipment and technology used in non-sterile compounding.   1.     5.2.5 Demonstrate the processes and procedures of non-sterile compounding.   1.     CONTENT STANDARD 6.0: PROCUREMENT, BILLING, REIMBURSEMENT, AND INVENTORY MANAGEMENT   Performance Standard 6.1: Adjudication of Billing     6.1.1 Define the term third party.   2.     6.1.2 Define the terminology used in insurance billing (e.g., prior authorizations, deductible, double billing) when supplies are billed as durable medical equipment.   2.     6.1.3 Describe the fields on an insurance card.   2.     6.1.4 Describe pharmacy reimbursement plans.   1.     6.1.5 Describe third-party rejections and the reasons they occur.   2.     Performance Standard 6.2: Purchasing Pharmaceuticals.   1.     6.2.1 Describe various procedures in purchasing pharmaceuticals.   1.     6.2.2 Describe controlled substance ordering systems (DEA Form 222).   1.     6.3.1 Differentiate inventory control systems for various drug classifications.   1.     6.3.2 Describe the procedures for rewiewing and removing outdated drug products.   2.		1.85
5.2.2 Describe USP Guideline 795 and its function.   1.     5.2.3 Identify the required ingredients for a compounded non-sterile product.   1.     5.2.4 Identify the equipment and technology used in non-sterile compounding.   1.     5.2.5 Demonstrate the processes and procedures of non-sterile compounding.   1.     S.2.5 Demonstrate the processes and procedures of non-sterile compounding.   1.     CONTENT STANDARD 6.0: PROCUREMENT, BILLING, REIMBURSEMENT, AND INVENTORY MANAGEMENT   Performance Standard 6.1: Adjudication of Billing     Performance Standard 6.1: Adjudication of Billing (e.g., prior authorizations, deductible, double billing) when supplies are billed as durable medical equipment.   2.     6.1.2 Define the terminology used in insurance billing (e.g., prior authorizations, deductible, double billing) when supplies are billed as durable medical equipment.   2.     6.1.4 Describe pharmacy rejections and the reasons they occur.   2.     Performance Standard 6.2: Purchasing Pharmaceuticals.   1.     6.2.1 Describe various procedures in purchasing pharmaceuticals.   1.     6.2.2 Describe controlled substance ordering systems (DEA Form 222).   1.     6.3.1 Differentiate inventory control systems for various drug classifications.   1.     6.3.1 Differentiate inventory control systems for various drug classifications.   2.     6.3.2 Describe the procedures for rewising and removing outd		
5.2.3 Identify the required ingredients for a compounded non-sterile product.   1.     5.2.4 Identify the equipment and technology used in non-sterile compounding.   1.     5.2.5 Demonstrate the processes and procedures of non-sterile compounding.   1.     CONTENT STANDARD 6.0: PROCUREMENT, BILLING, REIMBURSEMENT, AND INVENTORY MANAGEMENT   2.     Performance Standard 6.1: Adjudication of Billing   2.     6.1.1 Define the term third party.   2.     6.1.2 Define the term third party.   2.     6.1.3 Describe the fields on an insurance card.   2.     6.1.4 Describe thefields on an insurance card.   2.     6.1.5 Describe third-party rejections and the reasons they occur.   2.     Performance Standard 6.2: Purchasing pharmaceuticals.   1.     6.2.1 Describe various procedures in purchasing pharmaceuticals.   1.     6.3.1 Differentiate inventory control systems for various drug classifications.   1.     6.3.2 Describe the process of return to stock.   2.     6.3.3 Describe the procedures for revising and memory output drug products.   3.     6.3.4 Describe the procedures for revising and removing outdated drug products.   1.     6.3.2 Describe the procedures of revising and removing outdated drug products.   2.     6.3.2 Describe standard 6.3: Inventory Control		1.88
5.2.4 Identify the equipment and technology used in non-sterile compounding.   1.     5.2.5 Demonstrate the processes and procedures of non-sterile compounding.   1.     CONTENT STANDARD 6.0: PROCUREMENT, BILLING, REIMBURSEMENT, AND INVENTORY MANAGEMENT     Performance Standard 6.1: Adjudication of Billing     6.1.1 Define the term third party.   2.     6.1.2 Define the term inology used in insurance billing (e.g., prior authorizations, deductible, double billing) when supplies are billed as durable medical equipment.   2.     6.1.3 Describe the fields on an insurance card.   2.     6.1.4 Describe pharmacy reimbursement plans.   1.     6.1.5 Describe third-party rejections and the reasons they occur.   2.     Performance Standard 6.2: Purchasing Pharmaceuticals.     6.2.1 Describe various procedures in purchasing pharmaceuticals.   1.     6.2.2 Describe various procedures in purchasing pharmaceuticals.   1.     6.2.3 Describe the ordering systems (DEA Form 222).   1.     6.3.1 Differentiate inventory control systems for various drug classifications.   1.     6.3.2 Describe the process of return to stock.   2.     6.3.3 Describe the procedures for reviewing and removing outdated drug products.   2.     6.3.4 Describe the procedures for reviewing and removing outdated drug products.   2. <		1.71
5.2.5 Demonstrate the processes and procedures of non-sterile compounding.   1.     CONTENT STANDARD 6.0: PROCUREMENT, BILLING, REIMBURSEMENT, AND INVENTORY MANAGEMENT     Performance Standard 6.1: Adjudication of Billing   2.     6.1.1 Define the term third party.   2.     6.1.2 Define the term third party.   2.     6.1.3 Describe the terminology used in insurance billing (e.g., prior authorizations, deductible, double billing) when supplies are billed as durable medical equipment.   2.     6.1.4 Describe third-party reimbursement plans.   1.     6.1.5 Describe third-party rejections and the reasons they occur.   2.     Performance Standard 6.2: Purchasing Pharmaceuticals.   1.     6.2.1 Describe various procedures in purchasing pharmaceuticals.   1.     6.2.1 Describe various procedures in purchasing pharmaceuticals.   1.     6.2.1 Describe various procedures in purchasing pharmaceuticals.   1.     6.2.1 Describe ther ordering system of DEA Form 222).   1.     6.2.3 Describe the ordering systems for various drug classifications.   1.     6.3.1 Differentiate inventory control systems for various drug classifications.   1.     6.3.2 Describe the process of return to stock.   2.     6.3.3 Describe the procedures for reviving and removing outdated drug products.   2.     6.3.4 D		1.85
CONTENT STANDARD 6.0: PROCUREMENT, BILLING, REIMBURSEMENT, AND INVENTORY MANAGEMENT     Performance Standard 6.1: Adjudication of Billing   2.     6.1.1 Define the term third party.   2.     6.1.2 Define the term third party.   2.     6.1.3 Define the term third party.   2.     6.1.4 Define the term third party.   2.     6.1.3 Describe the fields on an insurance card.   2.     6.1.4 Describe pharmacy reimbursement plans.   1.     6.1.5 Describe third-party rejections and the reasons they occur.   2.     Performance Standard 6.2: Purchasing Pharmaceuticals.   1.     6.2.1 Describe various procedures in purchasing pharmaceuticals.   1.     6.2.2 Describe controlled substance ordering systems (DEA Form 222).   1.     6.3.3 Describe the process of return to stock.   2.     6.3.4 Describe the process of return to stock.   2.     6.3.5 Describe the procedure for removing recalled drugs from the pharmacy.   1.     6.3.4 Describe the procedure for removing recalled drugs from the pharmacy.   1.     6.3.5 Describe the procedure for removing recalled drugs from the pharmacy.   1.     6.3.6 Describe the procedure for removing recalled drugs from the pharmacy.   1.     6.3.7 Describe the procedure for removing recalled drugs from the pharmacy. <td></td> <td>1.85</td>		1.85
Performance Standard 6.1: Adjudication of Billing26.1.1 Define the term third party.2.6.1.2 Define the term third party.2.6.1.2 Define the terminology used in insurance billing (e.g., prior authorizations, deductible, double billing) when supplies are billed as durable medical equipment.2.6.1.3 Describe the fields on an insurance card.2.6.1.4 Describe pharmacy reimbursement plans.1.6.1.5 Describe third-party rejections and the reasons they occur.2.Performance Standard 6.2: Purchasing Pharmaceuticals1.6.2.1 Describe various procedures in purchasing pharmaceuticals.1.6.2.2 Describe controlled substance ordering systems (DEA Form 222).1.6.3.1 Differentiate inventory control systems for various drug classifications.1.6.3.2 Describe the ordering system and the technology applied.1.Performance Standard 6.3: Inventory Control2.6.3.1 Differentiate inventory control systems for various drug classifications.1.6.3.2 Describe the process of return to stock.2.6.3.3 Describe the procedure for removing recalled drugs from the pharmacy.1.6.3.4 Describe the procedures for reviewing and removing outdated drug products.2.6.3.7 Describe the legal requirements related to destroying controlled substances (DEA Form 41).1.Performance Standard 6.4: Customer Transactions2.6.3.7 Describe the process of reviewing and removing outdated drug products.2.6.3.6 Describe the process of or reviewing and removing outdated drug products.2.6.3.7 Describe the legal requirem	5.2.5 Demonstrate the processes and procedures of non-sterile compounding.	1.88
Performance Standard 6.1: Adjudication of Billing26.1.1 Define the term third party.2.6.1.2 Define the term third party.2.6.1.2 Define the terminology used in insurance billing (e.g., prior authorizations, deductible, double billing) when supplies are billed as durable medical equipment.2.6.1.3 Describe the fields on an insurance card.2.6.1.4 Describe pharmacy reimbursement plans.1.6.1.5 Describe third-party rejections and the reasons they occur.2.Performance Standard 6.2: Purchasing Pharmaceuticals1.6.2.1 Describe various procedures in purchasing pharmaceuticals.1.6.2.2 Describe controlled substance ordering systems (DEA Form 222).1.6.3.1 Differentiate inventory control systems for various drug classifications.1.6.3.2 Describe the ordering system and the technology applied.1.Performance Standard 6.3: Inventory Control2.6.3.1 Differentiate inventory control systems for various drug classifications.1.6.3.2 Describe the process of return to stock.2.6.3.3 Describe the procedure for removing recalled drugs from the pharmacy.1.6.3.4 Describe the procedures for reviewing and removing outdated drug products.2.6.3.7 Describe the legal requirements related to destroying controlled substances (DEA Form 41).1.Performance Standard 6.4: Customer Transactions2.6.3.7 Describe the process of reviewing and removing outdated drug products.2.6.3.6 Describe the process of or reviewing and removing outdated drug products.2.6.3.7 Describe the legal requirem		
6.1.1 Define the term third party.2.6.1.2 Define the terminology used in insurance billing (e.g., prior authorizations, deductible, double billing) when supplies are billed as durable medical equipment.2.6.1.3 Describe the fields on an insurance card.2.6.1.4 Describe pharmacy reimbursement plans.1.6.1.5 Describe third-party rejections and the reasons they occur.2.Performance Standard 6.2: Purchasing Pharmaceuticals1.6.2.1 Describe various procedures in purchasing pharmaceuticals.1.6.2.2 Describe the ordering system and the technology applied.1.Performance Standard 6.3: Inventory Control1.6.3.1 Differentiate inventory control systems for various drug classifications.1.6.3.2 Describe the process of return to stock.2.6.3.3 Describe the process of return to stock.1.6.3.4 Describe the process of return to stock.1.6.3.5 Describe the process of return to stock.1.6.3.6 Describe the procedures for reviewing and removing outdated drug products.2.6.3.6 Describe formularies in the pharmacy.1.6.3.7 Describe the legal requirements related to destroying controlled substances (DEA Form 41).1.Performance Standard 6.4: Customer Transactions for diverse populations.2.6.4.1 Demonstrate point of sale (POS) transactions for diverse populations.2.6.4.2 Describe the identifiers necessary to dispense medication.2.6.4.3 Describe trequired valid forms of identification for drug transactions and signature requirements.2.	CONTENT STANDARD 6.0: PROCUREMENT, BILLING, REIMBURSEMENT, AND INVENTORY MANAGEMENT	
6.1.2 Define the terminology used in insurance billing (e.g., prior authorizations, deductible, double billing) when supplies are billed as durable medical equipment.2.6.1.3 Describe the fields on an insurance card.2.6.1.4 Describe pharmacy reimbursement plans.1.6.1.5 Describe third-party rejections and the reasons they occur.2.Performance Standard 6.2: Purchasing Pharmaceuticals1.6.2.1 Describe various procedures in purchasing pharmaceuticals.1.6.2.2 Describe to rolled substance ordering systems (DEA Form 222).1.6.2.3 Describe the ordering system and the technology applied.1.Performance Standard 6.3: Inventory Control1.6.3.1 Differentiate inventory control systems for various drug classifications.1.6.3.2 Describe the process of return to stock.2.6.3.3 Describe the procedure for removing recalled drugs from the pharmacy.1.6.3.4 Describe the procedure for removing recalled drugs from the pharmacy.1.6.3.5 Describe the procedures for reviewing and removing outdated drug products.2.6.3.6 Describe the guirements related to destroying controlled substances (DEA Form 41).1.Performance Standard 6.4: Customer Transactions2.6.4.1 Demonstrate point of sale (POS) transactions for diverse populations.2.6.4.2 Describe patient identifiers necessary to dispense medication.2.6.4.3 Describe required valid forms of identification for drug transactions and signature requirements.2.	Performance Standard 6.1: Adjudication of Billing	
billed as durable medical equipment.2.6.1.3 Describe the fields on an insurance card.2.6.1.4 Describe pharmacy reimbursement plans.1.6.1.5 Describe third-party rejections and the reasons they occur.2.Performance Standard 6.2: Purchasing Pharmaceuticals1.6.2.1 Describe various procedures in purchasing pharmaceuticals.1.6.2.2 Describe controlled substance ordering systems (DEA Form 222).1.6.3.3 Describe the ordering system and the technology applied.1.Performance Standard 6.3: Inventory Control1.6.3.1 Differentiate inventory control systems for various drug classifications.1.6.3.2 Describe the process of return to stock.2.6.3.3 Describe the process of drug recalls.1.6.3.4 Describe the procedure for removing recalled drugs from the pharmacy.1.6.3.5 Describe the procedure for removing recalled drugs from the pharmacy.1.6.3.6 Describe the legal requirements related to destroying controlled substances (DEA Form 41).1.Performance Standard 6.4: Customer Transactions2.6.4.1 Demonstrate point of sale (POS) transactions for diverse populations.2.6.4.2 Describe pratient identifiers necessary to dispense medication.2.6.4.3 Describe required valid forms of identification for drug transactions and signature requirements.2.6.4.3 Describe required valid forms of identification for drug transactions and signature requirements.2.6.4.3 Describe required valid forms of identification for drug transactions and signature requirements.2.6.4.3 Describe required va	5.1.1 Define the term third party.	2.29
6.1.3 Describe the fields on an insurance card.2.6.1.4 Describe pharmacy reimbursement plans.1.6.1.5 Describe third-party rejections and the reasons they occur.2.Performance Standard 6.2: Purchasing Pharmaceuticals1.6.2.1 Describe various procedures in purchasing pharmaceuticals.1.6.2.2 Describe controlled substance ordering systems (DEA Form 222).1.6.2.3 Describe the ordering system and the technology applied.1.Performance Standard 6.3: Inventory Control6.6.3.1 Differentiate inventory control systems for various drug classifications.1.6.3.2 Describe the process of return to stock.2.6.3.3 Describe the procedure for removing recalled drugs from the pharmacy.1.6.3.4 Describe the procedures for reviewing and removing outdated drug products.2.6.3.5 Describe the legal requirements related to destroying controlled substances (DEA Form 41).1.Performance Standard 6.4: Customer Transactions2.6.4.1 Demonstrate point of sale (POS) transactions for diverse populations.2.6.4.2 Describe patient identifiers necessary to dispense medication.2.6.4.3 Describe required valid forms of identification for drug transactions and signature requirements.2.		2.34
6.1.4 Describe pharmacy reimbursement plans.1.6.1.5 Describe third-party rejections and the reasons they occur.2.Performance Standard 6.2: Purchasing Pharmaceuticals1.6.2.1 Describe various procedures in purchasing pharmaceuticals.1.6.2.2 Describe controlled substance ordering systems (DEA Form 222).1.6.2.3 Describe the ordering system and the technology applied.1.Performance Standard 6.3: Inventory Control1.6.3.1 Differentiate inventory control systems for various drug classifications.1.6.3.2 Describe the process of return to stock.2.6.3.3 Describe the procedure for removing recalled drugs from the pharmacy.1.6.3.4 Describe the procedure for removing recalled drugs from the pharmacy.1.6.3.5 Describe the procedures for reviewing and removing outdated drug products.2.6.3.6 Describe formularies in the pharmacy.1.6.3.7 Describe the legal requirements related to destroying controlled substances (DEA Form 41).1.Performance Standard 6.4: Customer Transactions2.6.4.1 Demonstrate point of sale (POS) transactions for diverse populations.2.6.4.3 Describe patient identifiers necessary to dispense medication.2.6.4.3 Describe required valid forms of identification for drug transactions and signature requirements.2.		
6.1.5 Describe third-party rejections and the reasons they occur.2.Performance Standard 6.2: Purchasing Pharmaceuticals1.6.2.1 Describe various procedures in purchasing pharmaceuticals.1.6.2.2 Describe controlled substance ordering systems (DEA Form 222).1.6.2.3 Describe the ordering system and the technology applied.1.Performance Standard 6.3: Inventory Control1.6.3.1 Differentiate inventory control systems for various drug classifications.1.6.3.2 Describe the process of return to stock.2.6.3.3 Describe the three classes of drug recalls.1.6.3.4 Describe the procedure for removing recalled drugs from the pharmacy.1.6.3.5 Describe the procedures for reviewing and removing outdated drug products.2.6.3.6 Describe formularies in the pharmacy.1.6.3.7 Describe the legal requirements related to destroying controlled substances (DEA Form 41).1.Performance Standard 6.4: Customer Transactions2.6.4.1 Demonstrate point of sale (POS) transactions for diverse populations.2.6.4.3 Describe required valid forms of identification for drug transactions and signature requirements.2.		2.39
Performance Standard 6.2: Purchasing Pharmaceuticals1.6.2.1 Describe various procedures in purchasing pharmaceuticals.1.6.2.2 Describe controlled substance ordering systems (DEA Form 222).1.6.2.3 Describe the ordering system and the technology applied.1.Performance Standard 6.3: Inventory Control1.6.3.1 Differentiate inventory control systems for various drug classifications.1.6.3.2 Describe the process of return to stock.2.6.3.3 Describe the three classes of drug recalls.1.6.3.4 Describe the procedure for removing recalled drugs from the pharmacy.1.6.3.5 Describe the procedures for reviewing and removing outdated drug products.2.6.3.6 Describe the legal requirements related to destroying controlled substances (DEA Form 41).1.Performance Standard 6.4: Customer Transactions2.6.4.1 Demonstrate point of sale (POS) transactions for diverse populations.2.6.4.3 Describe required valid forms of identification for drug transactions and signature requirements.2.		1.90
6.2.1 Describe various procedures in purchasing pharmaceuticals.1.6.2.2 Describe controlled substance ordering systems (DEA Form 222).1.6.2.3 Describe the ordering system and the technology applied.1.Performance Standard 6.3: Inventory Control6.3.1 Differentiate inventory control systems for various drug classifications.1.6.3.2 Describe the process of return to stock.2.6.3.3 Describe the three classes of drug recalls.1.6.3.4 Describe the procedure for removing recalled drugs from the pharmacy.1.6.3.5 Describe the procedures for reviewing and removing outdated drug products.2.6.3.6 Describe the legal requirements related to destroying controlled substances (DEA Form 41).1.Performance Standard 6.4: Customer Transactions2.6.4.1 Demonstrate point of sale (POS) transactions for diverse populations.2.6.4.3 Describe required valid forms of identification for drug transactions and signature requirements.2.		2.27
6.2.2 Describe controlled substance ordering systems (DEA Form 222).1.6.2.3 Describe the ordering system and the technology applied.1.Performance Standard 6.3: Inventory Control1.6.3.1 Differentiate inventory control systems for various drug classifications.1.6.3.2 Describe the process of return to stock.2.6.3.3 Describe the three classes of drug recalls.1.6.3.4 Describe the procedure for removing recalled drugs from the pharmacy.1.6.3.5 Describe standard procedures for reviewing and removing outdated drug products.2.6.3.6 Describe formularies in the pharmacy.1.6.3.7 Describe the legal requirements related to destroying controlled substances (DEA Form 41).1.Performance Standard 6.4: Customer Transactions2.6.4.1 Demonstrate point of sale (POS) transactions for diverse populations.2.6.4.3 Describe required valid forms of identification for drug transactions and signature requirements.2.		
6.2.3 Describe the ordering system and the technology applied.1.Performance Standard 6.3: Inventory Control6.3.1 Differentiate inventory control systems for various drug classifications.1.6.3.2 Describe the process of return to stock.2.6.3.3 Describe the three classes of drug recalls.1.6.3.4 Describe the procedure for removing recalled drugs from the pharmacy.1.6.3.5 Describe standard procedures for reviewing and removing outdated drug products.2.6.3.6 Describe formularies in the pharmacy.1.6.3.7 Describe the legal requirements related to destroying controlled substances (DEA Form 41).1.Performance Standard 6.4: Customer Transactions6.4.1 Demonstrate point of sale (POS) transactions for diverse populations.2.6.4.2 Describe required valid forms of identification for drug transactions and signature requirements.2.		1.66
Performance Standard 6.3: Inventory Control6.3.1 Differentiate inventory control systems for various drug classifications.1.6.3.2 Describe the process of return to stock.2.6.3.3 Describe the three classes of drug recalls.1.6.3.4 Describe the procedure for removing recalled drugs from the pharmacy.1.6.3.5 Describe standard procedures for reviewing and removing outdated drug products.2.6.3.6 Describe formularies in the pharmacy.1.6.3.7 Describe the legal requirements related to destroying controlled substances (DEA Form 41).1.Performance Standard 6.4: Customer Transactions2.6.4.1 Demonstrate point of sale (POS) transactions for diverse populations.2.6.4.2 Describe required valid forms of identification for drug transactions and signature requirements.2.		1.76
6.3.1 Differentiate inventory control systems for various drug classifications.1.6.3.2 Describe the process of return to stock.2.6.3.3 Describe the three classes of drug recalls.1.6.3.4 Describe the procedure for removing recalled drugs from the pharmacy.1.6.3.5 Describe standard procedures for reviewing and removing outdated drug products.2.6.3.6 Describe formularies in the pharmacy.1.6.3.7 Describe the legal requirements related to destroying controlled substances (DEA Form 41).1.Performance Standard 6.4: Customer Transactions2.6.4.1 Demonstrate point of sale (POS) transactions for diverse populations.2.6.4.2 Describe required valid forms of identification for drug transactions and signature requirements.2.		1.73
6.3.2 Describe the process of return to stock.2.6.3.3 Describe the three classes of drug recalls.1.6.3.4 Describe the procedure for removing recalled drugs from the pharmacy.1.6.3.5 Describe standard procedures for reviewing and removing outdated drug products.2.6.3.6 Describe formularies in the pharmacy.1.6.3.7 Describe the legal requirements related to destroying controlled substances (DEA Form 41).1.Performance Standard 6.4: Customer Transactions2.6.4.1 Demonstrate point of sale (POS) transactions for diverse populations.2.6.4.2 Describe patient identifiers necessary to dispense medication.2.6.4.3 Describe required valid forms of identification for drug transactions and signature requirements.2.	Performance Standard 6.3: Inventory Control	
6.3.3 Describe the three classes of drug recalls.1.6.3.4 Describe the procedure for removing recalled drugs from the pharmacy.1.6.3.5 Describe standard procedures for reviewing and removing outdated drug products.2.6.3.6 Describe formularies in the pharmacy.1.6.3.7 Describe the legal requirements related to destroying controlled substances (DEA Form 41).1.Performance Standard 6.4: Customer Transactions6.4.1 Demonstrate point of sale (POS) transactions for diverse populations.2.6.4.2 Describe patient identifiers necessary to dispense medication.2.6.4.3 Describe required valid forms of identification for drug transactions and signature requirements.2.	5.3.1 Differentiate inventory control systems for various drug classifications.	1.97
6.3.4 Describe the procedure for removing recalled drugs from the pharmacy.1.6.3.5 Describe standard procedures for reviewing and removing outdated drug products.2.6.3.6 Describe formularies in the pharmacy.1.6.3.7 Describe the legal requirements related to destroying controlled substances (DEA Form 41).1.Performance Standard 6.4: Customer Transactions2.6.4.1 Demonstrate point of sale (POS) transactions for diverse populations.2.6.4.2 Describe patient identifiers necessary to dispense medication.2.6.4.3 Describe required valid forms of identification for drug transactions and signature requirements.2.	5.3.2 Describe the process of return to stock.	2.21
6.3.5 Describe standard procedures for reviewing and removing outdated drug products.2.6.3.6 Describe formularies in the pharmacy.1.6.3.7 Describe the legal requirements related to destroying controlled substances (DEA Form 41).1.Performance Standard 6.4: Customer Transactions2.6.4.1 Demonstrate point of sale (POS) transactions for diverse populations.2.6.4.2 Describe patient identifiers necessary to dispense medication.2.6.4.3 Describe required valid forms of identification for drug transactions and signature requirements.2.	5.3.3 Describe the three classes of drug recalls.	1.74
6.3.6 Describe formularies in the pharmacy.1.6.3.7 Describe the legal requirements related to destroying controlled substances (DEA Form 41).1.Performance Standard 6.4: Customer Transactions2.6.4.1 Demonstrate point of sale (POS) transactions for diverse populations.2.6.4.2 Describe patient identifiers necessary to dispense medication.2.6.4.3 Describe required valid forms of identification for drug transactions and signature requirements.2.	5.3.4 Describe the procedure for removing recalled drugs from the pharmacy.	1.97
6.3.7 Describe the legal requirements related to destroying controlled substances (DEA Form 41).1.Performance Standard 6.4: Customer Transactions2.6.4.1 Demonstrate point of sale (POS) transactions for diverse populations.2.6.4.2 Describe patient identifiers necessary to dispense medication.2.6.4.3 Describe required valid forms of identification for drug transactions and signature requirements.2.	5.3.5 Describe standard procedures for reviewing and removing outdated drug products.	2.15
Performance Standard 6.4: Customer Transactions2.6.4.1 Demonstrate point of sale (POS) transactions for diverse populations.2.6.4.2 Describe patient identifiers necessary to dispense medication.2.6.4.3 Describe required valid forms of identification for drug transactions and signature requirements.2.	5.3.6 Describe formularies in the pharmacy.	1.77
6.4.1 Demonstrate point of sale (POS) transactions for diverse populations.2.6.4.2 Describe patient identifiers necessary to dispense medication.2.6.4.3 Describe required valid forms of identification for drug transactions and signature requirements.2.	5.3.7 Describe the legal requirements related to destroying controlled substances (DEA Form 41).	1.79
6.4.2 Describe patient identifiers necessary to dispense medication.2.6.4.3 Describe required valid forms of identification for drug transactions and signature requirements.2.	Performance Standard 6.4: Customer Transactions	
6.4.3 Describe required valid forms of identification for drug transactions and signature requirements. <b>2.</b>	5.4.1 Demonstrate point of sale (POS) transactions for diverse populations.	2.05
6.4.3 Describe required valid forms of identification for drug transactions and signature requirements. <b>2.</b>	5.4.2 Describe patient identifiers necessary to dispense medication.	2.54
	5.4.3 Describe required valid forms of identification for drug transactions and signature requirements.	2.54
		2.54
CONTENT STANDARD 7.0: SAFETY		
Performance Standards 7.1: Patient Safety		
		2.15
		1.77
7.1.3 Describe the roles of the Institute for Safe Medical Practices (ISMP), the Medical Error Reporting Program (MERP), and		
The Joint Commission (TJC).	The Joint Commission (TJC).	1.56
Performance Standard 7.2: Medication Safety	Performance Standard 7.2: Medication Safety	

7.2.1 Identify sound-alike/look-alike drugs.	2.33
7.2.2 Identify high-alert/high-risk medications.	2.31
7.2.3 Identify other common safety strategies for medications (e.g., cross-contamination, Tall-Man Lettering).	2.18
7.2.4 Describe the Tech-Check-Tech (TCT) program and its purpose.	1.97
7.2.5 Describe strategies for accurately receiving verbal orders.	2.36
CONTENT STANDARD 8.0: TECHNOLOGY AND INFORMATICS	
Performance Standard 8.1: Pharmaceutical Dispensing	
8.1.1 Describe the role of the Idaho Board of Pharmacy (BOP) requirements for dispensing medications.	2.49
8.1.2 Describe emerging technologies in the pharmacy industry.	1.36
8.1.3 Identify indicators of fraudulent prescriptions.	2.36
8.1.4 Describe reliable drug information resources and their purposes (e.g., Orange Book).	1.67
CONTENT STANDARD 9.0: PHARMACOLOGY	
Performance Standard 9.1: Pharmacokinetics and Pharmacodynamics	
9.1.1 Describe absorption, distribution, metabolism, excretion (ADME) and the related organs.	1.13
9.1.2 Identify pharmacological categories, their functions, and the common medications in each category.	1.56
9.1.3 Identify generic and brand names of common drugs.	2.23
9.1.4 Identify drug interactions/side-effects of commonly used medications.	1.26
9.1.5 Describe strengths/dosage, dosage forms.	2.05
9.1.6 Identify routes of administration.	2.23
Performance Standard 9.2: Over-The-Counter and Alternative Therapies	
9.2.1 Define over-the-counter (OTC) products.	2.34
9.2.2 Identify common over-the-counter (OTC) products.	2.05
9.2.3 Identify common vitamins, minerals, and herbal supplements.	1.82
9.2.4 Identify devices and durable medical equipment (DME).	1.58
CONTENT STANDARD 10.0: MATHEMATICS	
Performance Standard 10.1: Mathematics in Pharmaceutical Practice	
10.1.1 Convert between measurement systems (e.g., temperature conversions, conversions from household to metric).	2.26
10.1.2 Calculate ratios and proportions (i.e., dimensional analysis) for compounding sterile and non-sterile products.	2.08
10.1.3 Calculate drug concentrations as weight/weight, weight/volume, volume/volume.	1.92
10.1.4 Calculate dosages based on age, weight, body surface area, and drip rates.	1.87
10.1.5 Calculate "Days Supply,â€⊡based on a prescription.	2.66
10.1.6 Calculate "Quantity to Dispense,â€⊡based on a prescription.	2.63
10.1.7 Solve alligation calculations.	1.61
CONTENT STANDARD 11.0: QUALITY ASSURANCE	
Performance Standard 11.1: Assurance Practices	
11.1.1 Describe risk-management guidelines and regulations.	1.61
11.1.2 Describe National Drug Code (NDC) and its function.	2.26
11.1.3 Describe reporting agencies (e.g., MedWatch, Poison Control, pharmaceutical manufacturer, FDA Hotline) and their	4 50
	1.50